TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Iovance Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $15.88 and its highest was $54.21 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $3.87B.
What is Iovance Biotherapeutics’s price target?
The average price target for Iovance Biotherapeutics is $37.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $51.00 ,the lowest forecast is $22.00. The average price target represents 49.76% Increase from the current price of $24.96.
What do analysts say about Iovance Biotherapeutics?
Iovance Biotherapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Nov 10, 2021 which is in 2 months.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on Aug 05, 2021. The company reported -$0.529 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.017.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 155,030,000 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.529 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went up 3.246%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Among the largest hedge funds holding Iovance Biotherapeutics’s share is ARK Investment Management LLC. It holds Iovance Biotherapeutics’s shares valued at 480M.